Bio-Rad Laboratories (NYSE:BIO – Get Free Report) and OmniAb (NASDAQ:OABI – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations and institutional ownership.
Volatility & Risk
Bio-Rad Laboratories has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, OmniAb has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500.
Insider & Institutional Ownership
65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 72.1% of OmniAb shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 9.8% of OmniAb shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Bio-Rad Laboratories and OmniAb’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bio-Rad Laboratories | 39.45% | 3.64% | 2.55% |
| OmniAb | -108.11% | -16.74% | -14.79% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Bio-Rad Laboratories and OmniAb, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bio-Rad Laboratories | 0 | 4 | 1 | 0 | 2.20 |
| OmniAb | 1 | 0 | 3 | 0 | 2.50 |
Bio-Rad Laboratories currently has a consensus price target of $366.67, indicating a potential downside of 4.81%. OmniAb has a consensus price target of $11.50, indicating a potential upside of 128.40%. Given OmniAb’s stronger consensus rating and higher possible upside, analysts plainly believe OmniAb is more favorable than Bio-Rad Laboratories.
Valuation & Earnings
This table compares Bio-Rad Laboratories and OmniAb”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bio-Rad Laboratories | $2.58 billion | 3.99 | $759.90 million | $37.97 | 10.14 |
| OmniAb | $18.67 million | 39.04 | -$64.78 million | ($0.34) | -14.81 |
Bio-Rad Laboratories has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.
Summary
Bio-Rad Laboratories beats OmniAb on 9 of the 14 factors compared between the two stocks.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.
About OmniAb
OmniAb, Inc. is a biotechnology company that develops and licenses antibody discovery technologies for use in drug research and development. Its platform is designed to help biopharmaceutical companies generate fully human and species-diverse antibodies that can be evaluated as potential treatments for a range of diseases. The company’s technology portfolio includes genetically engineered animal platforms, such as OmniRat, OmniMouse and OmniChicken, which are used to produce antibody candidates against challenging biological targets.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
